Biopharmaceutical Practice

Understanding the Ecosystem for Biopharmaceutical Companies

The biopharmaceutical industry operates in a relative state of conflict. While the path of bringing new products to market is highly regulated through a predictable FDA approval process, the industry also weathers an ongoing series of sea changes from one decade to the next. As market dynamics shift, a company’s ability to succeed is dependent upon its ability to navigate these changes while remaining on course toward commercializing its products. Even the most sophisticated biopharmaceutical companies can benefit from a trusted advisor and many of those companies turn to Kineticos.

The Biopharmaceutical Practice at Kineticos

The Biopharmaceutical practice at Kineticos assists growth-oriented pharmaceutical and biotech companies realize their commercial potential at the corporate, portfolio and product levels. Our consulting team has a depth of expertise across functional areas and therapeutic areas, established through decades of work in consulting or in industry. Overall the practice has a strong commitment to client satisfaction and a proven ability to deliver results through practical solutions.

The Biopharmaceutical Practice at Kineticos supports clients across three service areas including:

Corporate Strategy & Development

  • Business Model Design
  • Portfolio Strategy
  • Geographic Market Entry Strategy
  • Opportunity Assessment
  • In- and Out- Licensing
  • Private Financing

Medical Affairs Strategy

  • Medical Affairs Strategic Planning & Operations
  • MSL Architecture, Management and Support
  • Real World Evidence/Registry Study

Commercial Strategy

  • New Product Planning
  • Strategic Launch Planning
  • Post-Marketing Strategy and Planning
  • Lifecycle Management
  • Marketing Excellence


  • Regulatory Strategy
  • Product Development
  • Regulatory Operations & Submissions Management

Click the Tabs Below for Biopharmaceutical Practice Case Studies, White Papers and Articles, and Blog


Case Studies
  • Portfolio Prioritization – Oncology

    Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus. 


    Read this Case Study

  • Oncology Commercial Assessment – Melanoma

    Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the


    Read this Case Study

  • Business Development & Licensing

    Situation: An innovative oncology diagnostics company retained Kineticos to assist in developing their pitch deck, as well as developing and


    Read this Case Study

  • Product Search

    Situation: A drug delivery technology company identified an opportunity to generate additional revenue by acquiring products to further develop and


    Read this Case Study

  • Commercial Assessment

    Situation: A mid-sized biotech company evaluating their Phase II Metabolic asset requested that Kineticos provide a commercial and financial assessment


    Read this Case Study

  • Business Development and Licensing

    Situation: A publicly traded pharmaceutical company seeking a strategic partner for their IND-ready asset was in need of support with


    Read this Case Study

  • 8 Key Principles to Building a Board of Directors

    There are too many great ideas that never reach the surface in our industry and that’s where Kineticos’ newest family


    Read this Article

  • The FDA’s Shift from Gate Keeper to Enabler

    Most of us were shocked when Scott Gottlieb stepped down from his duties as the FDA Commissioner. He is largely


    Read this Article

  • What Can China Teach Us About CAR-T?

    What Can China Teach Us About CAR T is the final installment of our CAR-T series and discusses how China


    Read this Article

  • Immuno-Oncology: In the Goldilocks Zone or Over-Invested?

    Written by Steve Buckanavage, Operating Executive, Kineticos It wasn’t that long ago that cancer was defined by the location in


    Read this Article

  • Staying the Course

    Written by Mark Osterman, Senior Vice President, Kineticos Kineticos recently announced Q4 2015 results of the Biopharma CEO Confidence Index,


    Read this Article

  • Cell and Gene Therapies: The Path to Commercialization

    Article Preview Regenerative Medicine holds enormous potential for treating and ameliorating many chronic conditions for which we do not yet


    Read this Article

  • Growth by Acquisition in Life Sciences: Do You Have a Plan?

    Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as


    Read this Blog Post

  • R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation

    James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?


    Read this Blog Post

  • Merck KGaA and Bayer Choose Opposite Strategies

    Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent


    Read this Blog Post

  • Foundation Medicine and Clovis Expand Partnership

    Article Preview In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion


    Read this Blog Post

  • Role of Companion Diagnostics in Immuno-oncology Race Unfolding

    Article Preview Important oncology events, including ASCO and ESMO, have recently displayed the fruits of the huge investment drug companies


    Read this Blog Post

  • Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity

    Article Preview As reported by Bloomberg and the Wall Street Journal, Bayer is expected to announce plans to sell its


    Read this Blog Post

Subscribe to our internal think tank, Kineticos Research Institute